Business Wire

University of Siena Researchers Demonstrate Rapid UV Disinfection of Operating Rooms Between Surgeries

14.4.2021 15:00:00 EEST | Business Wire | Press release

Share

UltraViolet Devices, Inc. (UVDI), a global leader in Ultraviolet Air and Surface disinfection, announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at the Society for Healthcare Epidemiology of America (SHEA) Spring Conference, taking place April 13-16, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005184/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

In the University of Siena research, the UVDI-360 Room Sanitizer effectively inactivated germs in operating rooms in six minutes. (Photo: Business Wire)

In the research, conducted by Dr. Gabriele Messina, Professor of Public Health, University of Siena at the Rugani Hospital Monteriggioni in Siena, the UVDI-360 Room Sanitizer achieved a greater than 97% germ reduction in operating rooms in only six minutes, with two three-minute disinfection cycles run on each side of the operating table. Testing the UVDI-360 Room Sanitizer’s use in-between surgeries prior to manual cleaning and disinfection was one of multiple environmental hygiene protocols examined in the research.

The Poster Abstract, “UVC in Hospital Theatre: A Hygiene Improvement” will be shared at SHEA during Poster Presentations on April 14-16.

“The results indicate that the use of the UVDI-360 produced high levels of disinfection in the operating room,” stated Dr. Gabriele Messina, Professor of Public Health, University of Siena. “As a complement to manual cleaning, which is key to remove gross filth and soil, these promising results underline the rapid, germicidal effectiveness of 254 nm UV-C in an operating room setting and can standardize the level of environmental hygiene for every single patient who undergoes surgery.”

Peter Veloz, Chief Executive Officer, UVDI, added, “This pioneering research verifies the ability to provide enhanced surface disinfection in operating rooms during the day without workflow disruption. As hospitals and surgery centers start to conduct more elective surgical procedures, a cleaner, safer operating room – at the pace healthcare facilities require – can be key to better patient outcomes.”

About UltraViolet Devices, Inc.

UVDI's Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California in the U.S.A., applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in published, clinical studies to reduce Healthcare-associated Infections and to inactivate high-risk pathogens. UVDI’s proven UV-C Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact | UVDI
Will Gerard
Director of Marketing
661.289.2741
will.gerard@uvdi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers

Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release

At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project

NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa

MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release

MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg

Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release

Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye